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We present a case of radiotherapy for a 66-year-old patient with squamous cell carcinoma on the left main bronchus
undergoing implantation of pacemaker, implantable cardioverter defibrillator (ICD) as well as cardiopulmonary support
(CPS) device. The radiation area was determined according to 4D List Mode positron emission tomography–computed
tomography (PET-CT) data. Planning Target Volume (PTV) included a part of the active ICD. For the optimal tumor
coverage and sparing of both the implantable cardiac devices and organs at risk, we combined the conformal
radiotherapy with stereotactic body radiotherapy (SBRT) using helical tomotherapy. The prescription dose of
25.2Gy was applied by conventional radiotherapy. SBRT was performed hypofractionated with a prescription dose
of 35Gy in 5 fractions. A dynamic electrocardiogram was performed during every radiation fraction. The implanted
aggregates were checked three times a week. Despite partial localization of the active ICD in the radiation field,
the tumor was treated without inappropriate shock delivery during radiation treatment and over twelve months
afterwards. The reduced tumor size as well as tumor metabolic activity were observed by PET-CT three months
after radiation treatment. The patient exhibited no signs of pneumonitis on the last radiological follow-up
examination six months after radiotherapy. The reduced dyspnea and cough over the first four months after
treatment were observed.
In conclusion, tumor shrinkage and temporary clinical improvement of the patient as well as no technical
complications of implanted cardiac devices were achieved by the radiation treatment.
Keywords: Pacemaker, Implantable cardioverter defibrillator, Cardiopulmonary support system, Helical
tomotherapy, Stereotactic radiotherapyBackground
There are no large clinical studies for the determination
of the exact radiation level that causes failure of the
cardiac pacemaker and ICD. Most radiotherapy depart-
ments are using the radiation dose constraints for im-
planted devices based on the sparse number of the case
reports and in vitro studies which occasionally demon-
strate different results [1-3]. The American Association
of Physicists in Medicine (AAPM) defined the guidelines
for the irradiation exposure of the cardiac pacemakers in
1994 [4]. These guidelines are based on the first generation
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unless otherwise stated.pacemakers and do not take into account the newer
radiation treatment technology. More recently, the Dutch
guideline based on the newer data of in vitro experiments
and several clinical studies was written [5]. These guide-
lines cover the recommendations for the irradiation of
ICDs and consider the modern radiotherapy techniques
such as intensity modulated radiation therapy (IMRT) or
arc technique. Some investigators demonstrated a predis-
position of batteries in modern cardiac pacemakers to
quicker or even sudden unloading by an accumulated dose
over 5Gy [3,6,7]. Radiation exposure of more than 2Gy is
rarely found when the location of the heart pacemaker is
outside the radiation field [8,9]. According to the data
of Mouton et al. the failure of actually used CMOS
pacemaker seems to appear at lower doses, also < 2Gy,
but in a high dose rate [10]. Last et al. and Wilm et al.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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heart pacemaker if possible <2Gy and by all means <10Gy,
with the lowest possible dose rate [11,12]. ICDs are more
sensitive to radiation than pacemakers because of scat-
tered radiation effect on the random access memory
(RAM) [13]. Manufacturers often provide the recommen-
dations on radiation tolerance of their produced devices.
However the recommended maximal dose tolerance dif-
fers considerably depending on the technical design of
machines. For example, St.-Jude Medical GmbH® recom-
mends the radiation dose limit for pacemaker by 20-30Gy
and for ICD the dose tolerance was not stated [7,14]. The
recommended dose limit for ICDs produced from Med-
tronic is variable from 1Gy to 5Gy depending on the
model of ICD [7,15]. These recommendations do not take
into consideration the recently used technical aspects and
physical property of radiation treatment. In the literature
we did not find any relevant information about radiation
dose constraints or radiation resistance for the case of
CPS device. We report here a possibility of the thoracic
radiotherapy for central bronchial carcinoma patient
with implanted cardiac pacemaker, ICD and assist de-
vice. . This case of radiation therapy is considered to be
complicated because the active ICD is partially located
in the radiation field.
Patient and methods
A 66-year-old patient with squamous cell carcinoma,
Grade II, on the left main bronchus, cT3 (5 cm) cN0
cM0 (Figure 1). A complete occlusion of the left upper
lobe and partial involvement of the left lower lobe were
detected by video-bronchoscopy. The general health con-
dition was complicated with a mild dyspnea at rest and
productive cough. The patient had initially undergone im-
plantation of the CMOS-based cardiac pacemaker due to
clinical relevant bradycardia developing on the basis of
ischemic cardiomyopathy. The implanted cardiac pace-
maker belongs to the “Accent” family pacemakers pro-
duced from St.-Jude Medical GmbH® (professional.sjm.
com/products/crm). Six months later an implantation of
the cardiac defibrillator was performed due to the firstFigure 1 Planning-PET-CT imaging by use of “fludeoxyglucose F 18” t
bronchus with restriction of those.attack of the ventricular tachyarrhythmia. The ICD was
activated shortly before radiation therapy due to a new
attack of the tachyarrhythmia. The implanted ICD
model – Atlas II VR SN – is the dual-chamber devices
with automatic vector switching algorithm and algorithms
for protection against inappropriate shock delivery
(http://matesa.com.sv/manuales/atlasIIVR.pdf ). A heart
assist device, namely left ventricular assist devices (LVAD),
was implanted two years later due to development of left
heart failure NYHA III. The CPS device belongs to the
long-term intracorporeal assisted system from company
“Novacor” [16,17].
The radiation dose of the implanted devices was calcu-
lated before radiotherapy using a phantom measuring as
well as during first three radiotherapy fractions by use of
the thermoluminescent detector (TLD) for the control
measurement.
Target movement caused by breathing and heart beat
was detected by 4D List Mode PET/CT (Figure 2). Dur-
ing this procedure the special integrated detector - Anzai
Gating system on the Siemens camera - registered the
motion amplitude of the indicated target during at least
ten minutes. Each 4D PET scan was reconstructed into an
ungated static image and analyzed by software [18,19].
2-field conformal radiotherapy prescribed to the 95%
isodose line followed by stereotactic radiotherapy using
helical tomotherapy and prescribed to the 65% isodose
line were sequentially applied (Figure 3a, b). The applied
prescription dose of conformal radiotherapy is composed
of 25.2Gy with 1.8Gy per fraction five times a week
using 6/15 MV photon beams. Stereotactic radiotherapy
was applied in a hypofractionated regime with the pre-
scription dose of 35Gy and 7Gy per fraction three times
a week by the use of 6MV photon beams.
The equipment that was maintained during radiation
treatment included ‘crash cart’ with CPR devices and de-
fibrillator with external pacemaker capacity. Electrocar-
diography (ECG) was performed during every treatment
session. A technical control of cardiac pacemaker and
defibrillators was performed three times a week during
conventional radiotherapy and after every stereotacticracer. Hypermetabolic activity of bronchial carcinoma on the left main
Figure 2 PTV in relation to implanted cardiac devices: a) breathing- and heart beat-guided definition of PTV on the basis of 4D List
Mode PET/CT; b) partial localization of the ICD in the radiation field. 1- cardiac pacemaker, 2 – ICD, 3 – CPS device.
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diac devices were checked weekly over the first month
and then monthly in the cardiology department.
Results
The maximal dose (Dmax) and median dose (Dmean) of
the active ICD partially situated in the radiation field
composed of 15.58Gy and 5.55Gy respectively. Dmax
and Dmean of the CPS device and pacemaker located
outside of the PTV composed of 5.38Gy/2.31Gy and
2.74Gy/1.13Gy respectively (Figure 4). Despite high radi-
ation exposure we observed neither permanent nor tem-
porary loss of function or inappropriate shock delivery
by ICD. The implanted devices showed a non-affected
function during radiation treatment and over the course
of twelve months afterwards. The radiation treatment
had generally no negative impact on the patient's cardiac
rhythm and blood circulation parameters. The treatment
response correlated with reduction of tumor size and
tumor metabolic activity as demonstrated three months
after radiotherapy by PET-CT (Figure 5a). Therefore, the
reduction of the maximal “standardized uptake value”
(SUV) in PET scans from pretreatment level of 14,8 to
6,1 was observed three months after radiation therapy.
Six months post radiation treatment a progressive disease
with new intrabronchial growth and enhanced metabolic
activity of primary tumor by maximal SUV 12,9 was veri-
fied (Figure 5b).Figure 3 Dose distribution in the radiation field: a) 2-field radiaton sc
SBRT prescribed to 65%-isodose line.The mean radiation dose for the ipsilateral lung com-
posed of 17.00Gy, and V20 demonstrated nearly 40% in
the dose volume histogram (40% of lung volume with ra-
diation dose of 20Gy) (Figure 4). This is high radiation
lung toxicity with the probability for radiation induced
pneumonitis from 30 to 40% [20,21]. On the other hand, a
forced expiratory pressure in 1 s (FEV1) of 75,9% (2,23 L)
from reference parameter in the pretherapeutical spir-
ometry pointed to sufficient pulmonary reserve by the
patient. According to our data the aggravated risk of
pneumonitis may develop by pretherapeutical FEV1
under 60% from reference parameter. Despite relative
high risk for the radiation induced pneumonitis, no clin-
ical and radiological signs of those were detected in the
course of six months after radiotherapy (the last radio-
logical follow-up examination) (Figure 5b). Moreover, the
patient exhibited a reduced dyspnea and cough over the
first four months after treatment. Sixteen months after ra-
diation treatment the patient died due to lung insuffi-
ciency induced by tumor progression with the developing
of massive ipsi- and contralateral pulmonal metastases.
Discussion
An impact of modern radiotherapy techniques or electro-
magnetic fields of linear accelerators, as well as dose rate
effects on the frequency and cause of device failures are
actually relevant to consider. So, the use of IMRT tech-
nique might lead to less radiation dose to pacemakershedule prescribed to 95%- isodose line; (b) IMRT-based plan for
Figure 4 Cumulative dose volume histogram. Evaluation of the additive radiation dose in the target volume as well as in the implanted
devices and organ at risk.
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At the same time, it is a prolonged radiotherapy treatment
with more additional fields for a better dose distribution,
what might produce the malfunction [3,7,22]. Hashii et al.
and Gelblum et al. demonstrated in vitro the higher neu-
trons production by use of beam energies above 10 MV,
what seem to generate the function defects of pacemakers
[23,24]. Elders et al. and Zaremba et al. observed the same
correlation between the ICDs malfunction and photon
beam energies ≥10 MeV in vivo studies. The authors hy-
pothesized that this correlation may be based on the inter-
action of neutrons produced in the head of the linear
accelerator at higher beam energies with boron situated in
the internal circuitry of ICD [25,26]. In 2002 Mouton
et al. published the largest study involved in vitro examin-
ation of dose rate effects on pacemaker's functionality[10]. No defects at the dose rate of 0.2 Gy/min. were ob-
served on the pacemakers studied. One could consider
this as the maximum acceptable dose rate.
The combination of SBRT and conventional radiother-
apy was applied for more effective local tumor control
via stereotactic radiotherapy. On the other hand, the
conventional radiation treatment is more suitable for the
sparing of the organ at risk especially for organ with the
slower cell turnover and lower α/β value, such as heart
and lung [27]. Of course, it is not fully correct to directly
summarize the doses from two different types of radiation
with different biological effectiveness. To our knowledge,
there are no calculation factors to relativize the hypofrac-
tional radiotherapy to conventional fractionated radiation
treatment. As the next step, we plan to introduce the spe-
cial weighting factors to evaluate more precisely the
Figure 5 Radiological follow-up staging after radiotherapy: a) significant reduction of tumor size and FDG-uptake in three months after
radiotherapy; b) progressive disease in six months with the intrabronchial tumor propagation and increased metabolic activity.
Scobioala et al. Radiation Oncology  (2015) 10:78 Page 5 of 7cumulative dose and respectively the summed biological
effect by the combination of conventional and hypofrac-
tional radiotherapy.
On the basis of some new clinical studies, the Dutch
guideline categorizes the radiotherapy patients into low,
medium and high risk groups [5]. The principal criterions
for this clinical classification are cumulative radiation dose
to pacemakers and pacing dependency of patients. Patients
with the radiation dose of less than 2 Gy are categorized as
low risk unless they are pace dependent. The medium risk
category consists of patients with doses between 2 and
10Gy, and the dose above 10Gy categorizes all patients of
high risk group. This risk dependent classification gives
some practical guidelines for the management of patients
having the cardiac rhythm machines. So, a cardiac moni-
toring (ECG) during every treatment session and device
checks within 24 hours after every fraction are needed to
be done when the cumulative dose is between 2Gy and
10Gy. For doses above 10Gy a relocation of the pace-
makers should be discussed. It is recommended to
monitor the pacemaker's functionality for at least the
first six months after radiation treatment [5,7].
It is necessary to calculate the dose received by the pace-
maker or ICD before radiation treatment. The use of more
modern planning system allows evaluating the received
dose in the radiation treatment plan by dose-volume his-
tograms. According to AAPM guideline a thermolumines-
cent dosimetry (TLDs) must be performed on day one to
check the dose received by the devices. Before radiother-
apy, we performed a phantom measuring in order to cal-
culate the potential irradiation dose for all implanted
devices. Additionally, a TLD measuring was performed
during the first three radiation sessions in order to controlthe received dose. Data from these measures demon-
strated radiation tolerance of the ICD with a maximal dose
of 15.85 Gy. The generally recommended safety measures
in terms of ICD as reprogramming of deactivating or ap-
plying a heavy magnet for the prevention of an inappropri-
ate shock delivery was not used during the radiation
treatment. Actually there are controversial opinions con-
cerning the effectiveness of these procedures and these
subjects should be considered in further examinations
[5,28,29]. In our case, the patient had an acute indication
for radiation treatment because of the rapid tumor pro-
gress. On the other side, the new attack of the ventricular
tachyarrhythmia shortly before radiotherapy has occurred.
In our opinion, it would be more perilous to inhibit the
antitachycardia therapy in this situation. There are a little
clinical data about the impact of the hypofractionated
schedules on the functionality of cardiac rhythm devices.
The higher fraction dose might have a higher probability
of the radiation induced malfunction. Although, using
IMRT based treatment a radiation exposure on devices
can be reduced by low energy photon beams. So, an SBRT
with 7Gy fraction dose in our case was applied using
tomotherapie with 6MV beam energies without any
technical dysfunction of pacemaker or ICD, or any clin-
ical consequences for the patient. In addition, the helical
tomotherapy schedule demonstrated an optimal ratio
between the tumor coverage and sparing of the cardiac
implantable machines. Both AAPM and Dutch guide-
lines recommended managing the dose distribution
without direct involvement of the electronic devices or
even with few centimeters distance of those from the ra-
diation field. In case of potentially high radiation dose,
the relocation of devices should be considered. The
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due to tumor expansion on implanted ICD (Figure 2).
Moreover, a clinical aggravation of the patient with rapidly
developing dyspnea at rest required a sooner beginning of
the palliative treatment. For this reason a high radiation ex-
posure of 15.85Gy (Dmax) was inevitable due to partial
localization of ICD in radiation area. ECG during every
radiotherapy session as well as technical control of devices
three times a week did not reveal any dysfunction of im-
planted machines. Also, no device failures such as inappro-
priate shock delivery were observed at all over the course
of one year after radiotherapy. To our knowledge, there is
no available data about radiation tolerance of the CPS de-
vice as well as influence of the electric and magnetic fields
of linear accelerators to the functionality of assist machine.
Interestingly, the high radiation exposure of the CPS ma-
chine with the maximal radiation dose of 5,38Gy (Dmax)
had no negative impact on cardiac and blood circulation
parameters in our case.
In order to achieve the optimal covering of tumor
area by minimal radiation exposure of the implantable
electronic rhythm devices and CPS machine, a stereo-
tactic radiotherapy schedule was evaluated. For this
purpose, a helical tomotherapy (Accuray Inc®, USA)
and Intensity Modulated Arc Therapy (IMAT) for
TrueBeam LINAC (Varian Medical Systems®, USA)
were scheduled. Tomotherapy demonstrated better tumor
coverage as well as sparing of implanted machines despite
a little increased radiation dose of ipsi- and contralateral
lung. The reduced lung toxicity was minimized by 2-field
conformal radiotherapy. Thus, the combination of stereo-
taxic hypofractional radiotherapy with conformal external
beam radiation was able to deliver the optimal dose distri-
bution with sparing all risk structures.
Conclusions
The presented case demonstrates both a temporal clin-
ical improvement of the palliative patient as well as high
radiation tolerance of ICD partially located in radiation
area. Despite extremely high radiation dose to ICD, no
dysfunction such as inappropriate shock delivery was ob-
served at all. The demonstrated radiation treatment is
based on individual concept. This therapy was only pos-
sible through multidisciplinary team of expert cardiolo-
gists, medical physicists and radiation oncologists.
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